"Transgene SA (TNG.PA) (TNG.PA) today announced promising results in an update incorporating more mature data from the Phase 2b part of the Phase 2b/3 TIME trial1 with TG4010 MUC-1 targeted immunotherapy in patients with advanced non-small cell lung cancer (NSCLC).
"Following an analysis conducted with a more mature dataset, the primary endpoint of progression-free survival (PFS) to validate the TrPAL predictive biomarker was met2 in the normal TrPAL3 group. The high TrPAL group had not yet met the required number of events to conduct the primary analysis."
Editor's note: This clinical trial is testing whether an immunotherapy drug called TG4010 MUC-1 might be effective for some patients with non-small cell lung cancer (NSCLC). For more information, see this trial in our Clinical Trial Finder.